You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Banner image with blue and red molecule

Pipeline Information

Development Programs – Solid Tumor

Drug

Indication

Phase 1

Phase 2

Phase 3


BGB-24714 (SMAC Mimetic) +/- Chemotherapy

Advanced Solid Tumors

BGB-3245

(BRAF inhibitor)
Advanced solid tumors with BRAF mutations

BGB-24714 (SMAC Mimetic) +/- Chemotherapy

(RAF inhibitor) + Mirdametinib (MEK inhibitor)
Advanced solid tumors

Tislelizumab + Ociperlimab

(anti-TIGIT)
1L PD-L1 high advanced NSCLC

2L PD-L1+ advanced ESCC

2L + cervical cancer

Advanced solid tumors

Ociperlimab + Tislelizumab + BAT1706 (anti-VEGF)

1L HCC

Ociperlimab + Tislelizumab + Chemotherapy

1L NSCLC

Tislelizumab + Ociperlimab + Concurrent Chemoradiotherapy

Previously untreated, stage III unresectable NSCLC

Previously untreated LS-SCLC

Pamiparib

(PARP 1-2 inhibitor)
2L/3L maintenance platinum-sensitive OC

1L maintenance platinum-sensitive GC

Advanced OC and TNBC

Pamiparib + Temozolomide

Advanced solid tumors

Tislelizumab

2L advanced ESCC

1L HCC

2L/3L NSCLC

Previously treated unresectable HCC

1L MSI-H or dMMR CRC

Previously treated advanced MSI-high or dMMR solid tumors

Tislelizumab + Surzebiclimab

(anti-TIM-3)
Advanced solid tumors

Tislelizumab + BGB-A445

(anti-OX40)
Advanced solid tumors

Tislelizumab + BGB-10188

(PI3K inhibitor)
Advanced solid tumors

Tislelizumab + BGB-15025

(HPK1 inhibitor)
Advanced solid tumors

Tislelizumab + Chemoradiotherapy

Localized ESCC

Tislelizumab + Chemotherapy/ Chemoradiotherapy

Resectable ESCC

Tislelizumab + Chemotherapy

1L advanced ESCC

1L GC/GEJC

Resectable stage II or IIIA NSCLC

1L advanced nasopharyngeal cancer

1L squamous NSCLC

1L non-squamous NSCLC

1L advanced UBC

1L ES-SCLC

Tislelizumab + DKN-01

(anti-DKK1) + Chemotherapy
1L/2L GC/GEJ

Tislelizumab + Fruquintinib

(VEGFR inhibitor)
Advanced or metastatic, unresectable GC, CRC, NSCLC

Advanced triple negative BC

Tislelizumab + Lenvatinib

(VEGFR kinase inhibitor)
1L HCC

Advanced solid tumors

Tislelizumab + Sitravatinib

(multikinase inhibitor)
Advanced NSCLC after anti-PD-(L)1 therapy

Advanced GC/GEJC/HCC

Advanced solid tumors

Tislelizumab + Surufatinib

(VEGFR, FGFR, CSF-1R inhibitor)
Advanced solid tumors

Zanidatamab

(anti-HER2 bi-specific antibody)
2L+ HER2+ BTC

Zanidatamab + Chemotherapy+/- Tislelizumab

1L HER2+ BC and 1L HER2+ GC/GEJC

1L HER2+ advanced/metastatic GC/EC

Australia
Australia, China
Australia, US
China
China, S. Korea
China, Thailand
S. Korea, US
United States
Worldwide

BC, breast cancer; BRAF, B-Raf proto-oncogene; BRCA+, breast cancer susceptibility gene-positive; BTC, biliary tract cancer; dMMR, deficient mismatch repair; ESCC, esophageal squamous cell carcinoma; ES-SCLC; extensive-stage small cell lung cancer; GBM, glioblastoma multiforme; GC, gastric cancer; GEJC, gastroesophageal junction carcinoma; HCC, hepatocelluar carcinoma; HER2-, human epidermal growth factor receptor-2–negative; HER2+, human epidermal growth factor receptor-2–positive; MSI, microsatellite instability; NSCLC, non-small cell lung cancer; OC, ovarian cancer; R/R, recurrent/refractory; SCLC, small lung cell cancer; TNBC, triple-negative breast cancer; UBC, urothelial bladder cancer.

Development Programs – Hematology

Drug

Indication

Phase 1

Phase 2

Phase 3


Tislelizumab

(anti-PD-1)
R/R cHL

R/R cHL

BGB-10188

(PI3K inhibitor) +/- Tislelizumab
B-cell malignancies

BGB-10188

(PI3K inhibitor) +/- Zanubrutinib (BTK inhibitor)
B-cell lymphoid malignancies

BGB-11417

(Bcl-2 inhibitor) monotherapy
B-cell malignancies

BGB-11417 + Azacitidine +/- Posaconazole

Myeloid malignancies

BGB-11417 + Dexamethasone +/- Carfilzomib

R/R multiple myeloma with t(11;14)

BGB-11417

monotherapy + zanubrutinib
B-cell malignancies

BGB-16673

(BTK-targeted CDAC)
B-cell malignancies

B-cell malignancies

Ociperlimab

(anti-TIGIT) +/- Tislelizumab or Rituximab
R/R DLBCL

Zandelisib

Zanubrutinib or Rituximab*
CLL/SLL and B-cell NHL

Zanubrutinib

R/R CLL/SLL

CD79B R/R DLBCL

Previously treated B-cell malignancies

B-cell malignancies

Zanubrutinib + Lenalidomide +/- Rituximab

R/R DLBCL

Zanubrutinib

+ Obinutuzumab (anti-CD20)
R/R FL

Zanubrutinib + Rituximab

(anti-CD20)
1L MCL

R/R MZL

Zanubrutinib +/- Venetoclax

(Bcl-2 inhibitor)
1L CLL/SLL

Australia
Australia, US
China
Japan
Switzerland, US
United States
Worldwide

* In collaboration with MEI Pharma
This combination is being studied in the third cohort of NCT03336333

CDAC chimeric degradation activating compound; B-cell NHL, B-cell non-Hodgkins lymphoma; cHL, classical Hodgkin lymphoma; CLL, chronic lymphotic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; GCB, germinal center B cell-like; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; NK, natural killer; R/R, recurrent/refractory; SLL, small lymphocytic lymphoma; WM, Waldenstrӧm macroglobulinemia.

Videos

PARPI Mechanism of Action

Anti-PD-1 Mechanism of Action

BTKI Mechanism of Action

Anti-TIGIT Mechanism of Action